Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.
2.
3.

Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group.

Marshall SA, Erwin ME, Jones RN.

J Clin Microbiol. 2000 Jun;38(6):2462-3. No abstract available.

5.

Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.

Jones RN, Deshpande LM, Erwin ME, Barrett MS, Beach ML.

J Antimicrob Chemother. 2000 Apr;45 Suppl 1:67-70.

PMID:
10824035
6.

Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.

Jones RN, Erwin ME, Biedenbach DJ, Johnson DM, Pfaller MA.

Diagn Microbiol Infect Dis. 1999 Nov;35(3):227-34.

PMID:
10626134
9.

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates.

Hayward CL, Erwin ME, Barrett MS, Jones RN.

Diagn Microbiol Infect Dis. 1999 Jun;34(2):99-102.

PMID:
10354858
10.

Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.

Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ, Pfaller MA.

Diagn Microbiol Infect Dis. 1999 Jun;34(2):91-8.

PMID:
10354857
12.
13.
18.
19.
20.

Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.

Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, Edmond MB, Wenzel RP.

Diagn Microbiol Infect Dis. 1997 Oct;29(2):95-102.

PMID:
9368085
21.

In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.

Erwin ME, Varnam D, Jones RN.

Diagn Microbiol Infect Dis. 1997 Jun;28(2):93-100.

PMID:
9239501
22.

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

Jones RN, Barrett MS, Erwin ME.

Antimicrob Agents Chemother. 1997 Feb;41(2):488-93.

23.

Critical appraisal of E test for the detection of fluoroquinolone resistance.

Jones RN, Erwin ME, Croco JL.

J Antimicrob Chemother. 1996 Jul;38(1):21-5.

PMID:
8858453
25.

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Jones RN, Johnson DM, Erwin ME.

Antimicrob Agents Chemother. 1996 Mar;40(3):720-6.

26.

Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.

Cormican MG, Erwin ME, Marshall SA, Jones RN.

Diagn Microbiol Infect Dis. 1996 Mar;24(3):155-60.

PMID:
8724401
28.

False resistance to metronidazole by E-test among anaerobic bacteria investigations of contributing test conditions and medium quality.

Cormican MG, Erwin ME, Jones RN.

Diagn Microbiol Infect Dis. 1996 Feb;24(2):117-9. No abstract available.

PMID:
9147908
29.

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1.

Doern GV, Jones RN, Gerlach EH, Washington JA, Biedenbach DJ, Brueggemann A, Erwin ME, Knapp C, Raymond J.

J Clin Microbiol. 1995 Jun;33(6):1665-7.

30.

Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis.

Croco JL, Erwin ME, Jennings JM, Putnam LR, Jones RN.

Clin Infect Dis. 1995 Jun;20 Suppl 2:S339-41. No abstract available.

PMID:
7548592
32.
33.
34.

Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis.

Sader HS, Runyon BA, Erwin ME, Jones RN.

Diagn Microbiol Infect Dis. 1995 Feb;21(2):105-10.

PMID:
7628189
35.

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.

Jones RN, Kehrberg EN, Erwin ME.

Drugs. 1995;49 Suppl 2:179-81. No abstract available.

PMID:
8549295
36.

Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis.

Croco JL, Erwin ME, Jennings JM, Putnam LR, Jones RN.

Diagn Microbiol Infect Dis. 1994 Dec;20(4):213-9.

PMID:
7705035
38.

Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.

Murphy SP, Erwin ME, Jones RN.

Diagn Microbiol Infect Dis. 1994 Sep;20(1):49-55.

PMID:
7867299
40.

Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.

Koontz FP, Erwin ME, Barrett MS, Jones RN.

Diagn Microbiol Infect Dis. 1994 Jul;19(3):183-6.

PMID:
7821001
43.

Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.

Jones RN, Johnson DM, Erwin ME.

Diagn Microbiol Infect Dis. 1994 Feb;18(2):125-7.

PMID:
8062531
44.

In-vitro activity of FK-037, a new parenteral cephalosporin.

Jones RN, Barrett MS, Erwin ME.

J Antimicrob Chemother. 1994 Jan;33(1):137-44. No abstract available.

PMID:
8157554
45.

E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.

Hughes JH, Biedenbach DJ, Erwin ME, Jones RN.

J Clin Microbiol. 1993 Dec;31(12):3255-9.

46.

In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.

Marshall SA, Jones RN, Murray PR, Washington JA, Allen SD, Gerlach EH, Erwin ME.

J Antimicrob Chemother. 1993 Dec;32(6):877-84. No abstract available.

PMID:
8144428
47.
48.
49.

Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae.

Barrett MS, Jones RN, Erwin ME.

Diagn Microbiol Infect Dis. 1993 Oct;17(3):243-5.

PMID:
8112036

Supplemental Content

Loading ...
Support Center